5wb8 › Citations

EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics.

Freed DM, Bessman NJ, Kiyatkin A, Salazar-Cavazos E, Byrne PO, Moore JO, Valley CC, Ferguson KM, Leahy DJ, Lidke DS, Lemmon MA
Cell 171 683-695.e18 (2017)
Cited: 155 times
EuropePMC logo PMID: 28988771

Abstract

Epidermal growth factor receptor (EGFR) regulates many crucial cellular programs, with seven different activating ligands shaping cell signaling in distinct ways. Using crystallography and other approaches, we show how the EGFR ligands epiregulin (EREG) and epigen (EPGN) stabilize different dimeric conformations of the EGFR extracellular region. As a consequence, EREG or EPGN induce less stable EGFR dimers than EGF-making them partial agonists of EGFR dimerization. Unexpectedly, this weakened dimerization elicits more sustained EGFR signaling than seen with EGF, provoking responses in breast cancer cells associated with differentiation rather than proliferation. Our results reveal how responses to different EGFR ligands are defined by receptor dimerization strength and signaling dynamics. These findings have broad implications for understanding receptor tyrosine kinase (RTK) signaling specificity. Our results also suggest parallels between partial and/or biased agonism in RTKs and G-protein-coupled receptors, as well as new therapeutic opportunities for correcting RTK signaling output.

Articles - 5wb8 mentioned but not cited (4)

  1. EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics. Freed DM, Bessman NJ, Kiyatkin A, Salazar-Cavazos E, Byrne PO, Moore JO, Valley CC, Ferguson KM, Leahy DJ, Lidke DS, Lemmon MA. Cell 171 683-695.e18 (2017)
  2. Cellular, transcriptomic and isoform heterogeneity of breast cancer cell line revealed by full-length single-cell RNA sequencing. Wu S, Zhang H, Fouladdel S, Li H, Keller E, Wicha MS, Omenn GS, Azizi E, Guan Y. Comput Struct Biotechnol J 18 676-685 (2020)
  3. Predicted structural mimicry of spike receptor-binding motifs from highly pathogenic human coronaviruses. Beaudoin CA, Jamasb AR, Alsulami AF, Copoiu L, van Tonder AJ, Hala S, Bannerman BP, Thomas SE, Vedithi SC, Torres PHM, Blundell TL. Comput Struct Biotechnol J 19 3938-3953 (2021)
  4. A toolkit for recombinant production of seven human EGF family growth factors in active conformation. Ferreira AS, Lopacinski A, Batista M, Hiraiwa PM, Guimarães BG, Zanchin NIT. Sci Rep 12 5034 (2022)


Reviews citing this publication (40)

  1. Emerging functions of the EGFR in cancer. Sigismund S, Avanzato D, Lanzetti L. Mol Oncol 12 3-20 (2018)
  2. Structural insights into G-protein-coupled receptor allostery. Thal DM, Glukhova A, Sexton PM, Christopoulos A. Nature 559 45-53 (2018)
  3. Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges. Butti R, Das S, Gunasekaran VP, Yadav AS, Kumar D, Kundu GC. Mol Cancer 17 34 (2018)
  4. Differential effects of transient and sustained activation of BDNF-TrkB signaling. Guo W, Nagappan G, Lu B, Lu B. Dev Neurobiol 78 647-659 (2018)
  5. Prospects for pharmacological targeting of pseudokinases. Kung JE, Jura N. Nat Rev Drug Discov 18 501-526 (2019)
  6. Receptor tyrosine kinase activation: From the ligand perspective. Trenker R, Jura N. Curr Opin Cell Biol 63 174-185 (2020)
  7. Akt-ing Up Just About Everywhere: Compartment-Specific Akt Activation and Function in Receptor Tyrosine Kinase Signaling. Sugiyama MG, Fairn GD, Antonescu CN. Front Cell Dev Biol 7 70 (2019)
  8. Power to the protein: enhancing and combining activities using the Spy toolbox. Keeble AH, Howarth M. Chem Sci 11 7281-7291 (2020)
  9. A threshold model for receptor tyrosine kinase signaling specificity and cell fate determination. Zinkle A, Mohammadi M. F1000Res 7 F1000 Faculty Rev-872 (2018)
  10. The RTK Interactome: Overview and Perspective on RTK Heterointeractions. Paul MD, Hristova K. Chem Rev 119 5881-5921 (2019)
  11. Communication codes in developmental signaling pathways. Li P, Elowitz MB. Development 146 dev170977 (2019)
  12. The Role of EREG/EGFR Pathway in Tumor Progression. Cheng WL, Feng PH, Lee KY, Chen KY, Sun WL, Van Hiep N, Luo CS, Wu SM. Int J Mol Sci 22 12828 (2021)
  13. Thirty Years of HER3: From Basic Biology to Therapeutic Interventions. Haikala HM, Jänne PA. Clin Cancer Res 27 3528-3539 (2021)
  14. MAPK and PI3K signaling: At the crossroads of neural crest development. Dinsmore CJ, Soriano P. Dev Biol 444 Suppl 1 S79-S97 (2018)
  15. Mechanisms of Receptor Tyrosine-Protein Kinase ErbB-3 (ERBB3) Action in Human Neoplasia. Black LE, Longo JF, Carroll SL. Am J Pathol 189 1898-1912 (2019)
  16. Receptor-Receptor Interactions as a Widespread Phenomenon: Novel Targets for Drug Development? Guidolin D, Marcoli M, Tortorella C, Maura G, Agnati LF. Front Endocrinol (Lausanne) 10 53 (2019)
  17. Emerging Allosteric Mechanism of EGFR Activation in Physiological and Pathological Contexts. Tsai CJ, Nussinov R. Biophys J 117 5-13 (2019)
  18. Structure and Dynamics of the EGF Receptor as Revealed by Experiments and Simulations and Its Relevance to Non-Small Cell Lung Cancer. Martin-Fernandez ML, Clarke DT, Roberts SK, Zanetti-Domingues LC, Gervasio FL. Cells 8 E316 (2019)
  19. Insulin and epidermal growth factor receptor family members share parallel activation mechanisms. Ferguson KM, Hu C, Lemmon MA. Protein Sci 29 1331-1344 (2020)
  20. A novel ligand-receptor relationship between families of ribonucleases and receptor tyrosine kinases. Wang YN, Lee HH, Hung MC. J Biomed Sci 25 83 (2018)
  21. More than the sum of the parts: Toward full-length receptor tyrosine kinase structures. Diwanji D, Thaker T, Jura N. IUBMB Life 71 706-720 (2019)
  22. Regulation of EGFR signalling by palmitoylation and its role in tumorigenesis. Kadry YA, Lee JY, Witze ES. Open Biol 11 210033 (2021)
  23. Ligand bias in receptor tyrosine kinase signaling. Karl K, Paul MD, Pasquale EB, Hristova K. J Biol Chem 295 18494-18507 (2020)
  24. Modulation of Pathological Pain by Epidermal Growth Factor Receptor. Borges JP, Mekhail K, Fairn GD, Antonescu CN, Steinberg BE. Front Pharmacol 12 642820 (2021)
  25. It Takes More than Two to Tango: Complex, Hierarchal, and Membrane-Modulated Interactions in the Regulation of Receptor Tyrosine Kinases. Kovacs T, Zakany F, Nagy P. Cancers (Basel) 14 944 (2022)
  26. EGFR, the Lazarus target for precision oncology in glioblastoma. Lin B, Ziebro J, Smithberger E, Skinner KR, Zhao E, Cloughesy TF, Binder ZA, O'Rourke DM, Nathanson DA, Furnari FB, Miller CR. Neuro Oncol 24 2035-2062 (2022)
  27. Exploitation of receptor tyrosine kinases by viral-encoded growth factors. Lateef Z, Wise LM. Growth Factors 36 118-140 (2018)
  28. Emerging Role of EGFR Mutations in Creating an Immune Suppressive Tumour Microenvironment. Kapoor SS, Zaiss DMW. Biomedicines 10 52 (2021)
  29. Evolving Experimental Techniques for Structure-Based Drug Design. Aplin C, Milano SK, Zielinski KA, Pollack L, Cerione RA. J Phys Chem B 126 6599-6607 (2022)
  30. Cryo-electron Microscopic Analysis of Single-Pass Transmembrane Receptors. Cai K, Zhang X, Bai XC. Chem Rev 122 13952-13988 (2022)
  31. ERK1/2-RSK2 Signaling in Regulation of ERα-Mediated Responses. Lannigan DA. Endocrinology 163 bqac106 (2022)
  32. Expanding the Disorder-Function Paradigm in the C-Terminal Tails of Erbbs. Pinet L, Assrir N, van Heijenoort C. Biomolecules 11 1690 (2021)
  33. Fluorescence Imaging of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer. Martin-Fernandez ML. Cancers (Basel) 14 686 (2022)
  34. Diffusion-based determination of protein homodimerization on reconstituted membrane surfaces. Jepson TA, Chung JK. BMB Rep 54 157-163 (2021)
  35. Epidermal Growth Factor Receptor-Targeted Neoantigen Peptide Vaccination for the Treatment of Non-Small Cell Lung Cancer and Glioblastoma. Li F, Wu H, Du X, Sun Y, Rausseo BN, Talukder A, Katailiha A, Elzohary L, Wang Y, Wang Z, Lizée G. Vaccines (Basel) 11 1460 (2023)
  36. Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications. Kciuk M, Alam M, Ali N, Rashid S, Głowacka P, Sundaraj R, Celik I, Yahya EB, Dubey A, Zerroug E, Kontek R. Molecules 28 5246 (2023)
  37. PI3K signaling through a biochemical systems lens. Madsen RR, Toker A. J Biol Chem 299 105224 (2023)
  38. Pondering the mechanism of receptor tyrosine kinase activation: The case for ligand-specific dimer microstate ensembles. Karl K, Hristova K. Curr Opin Struct Biol 71 193-199 (2021)
  39. Research on the biological mechanism and potential application of CEMIP. Liu Y, Hu G, Li Y, Kong X, Yang K, Li Z, Lao W, Li J, Zhong J, Zhang S, Leng Y, Bi C, Zhai A. Front Immunol 14 1222425 (2023)
  40. Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer. Cao Y, Efetov SK, He M, Fu Y, Beeraka NM, Zhang J, Zhang X, Bannimath N, Chen K. Arch Immunol Ther Exp (Warsz) 71 19 (2023)

Articles citing this publication (111)

  1. Current Challenges and Opportunities in Treating Glioblastoma. Shergalis A, Bankhead A, Luesakul U, Muangsin N, Neamati N. Pharmacol Rev 70 412-445 (2018)
  2. A Macrophage-Pericyte Axis Directs Tissue Restoration via Amphiregulin-Induced Transforming Growth Factor Beta Activation. Minutti CM, Modak RV, Macdonald F, Li F, Smyth DJ, Dorward DA, Blair N, Husovsky C, Muir A, Giampazolias E, Dobie R, Maizels RM, Kendall TJ, Griggs DW, Kopf M, Henderson NC, Zaiss DM. Immunity 50 645-654.e6 (2019)
  3. Visualization of ligand-induced transmembrane signaling in the full-length human insulin receptor. Gutmann T, Kim KH, Grzybek M, Walz T, Coskun Ü. J Cell Biol 217 1643-1649 (2018)
  4. Topological control of cytokine receptor signaling induces differential effects in hematopoiesis. Mohan K, Ueda G, Kim AR, Jude KM, Fallas JA, Guo Y, Hafer M, Miao Y, Saxton RA, Saxton RA, Piehler J, Sankaran VG, Baker D, Garcia KC. Science 364 eaav7532 (2019)
  5. Cryo-EM structure of the complete and ligand-saturated insulin receptor ectodomain. Gutmann T, Schäfer IB, Poojari C, Brankatschk B, Vattulainen I, Strauss M, Coskun Ü. J Cell Biol 219 e201907210 (2020)
  6. Light-based tuning of ligand half-life supports kinetic proofreading model of T cell signaling. Tischer DK, Weiner OD. Elife 8 e42498 (2019)
  7. Phosphorylated EGFR Dimers Are Not Sufficient to Activate Ras. Liang SI, van Lengerich B, Eichel K, Cha M, Patterson DM, Yoon TY, von Zastrow M, Jura N, Gartner ZJ. Cell Rep 22 2593-2600 (2018)
  8. Regulation of Collective Metastasis by Nanolumenal Signaling. Wrenn ED, Yamamoto A, Moore BM, Huang Y, McBirney M, Thomas AJ, Greenwood E, Rabena YF, Rahbar H, Partridge SC, Cheung KJ. Cell 183 395-410.e19 (2020)
  9. Cryo-EM analyses reveal the common mechanism and diversification in the activation of RET by different ligands. Li J, Shang G, Chen YJ, Brautigam CA, Liou J, Zhang X, Bai XC. Elife 8 e47650 (2019)
  10. Drosophila Insulin-Like Peptides DILP2 and DILP5 Differentially Stimulate Cell Signaling and Glycogen Phosphorylase to Regulate Longevity. Post S, Karashchuk G, Wade JD, Sajid W, De Meyts P, Tatar M. Front Endocrinol (Lausanne) 9 245 (2018)
  11. Multi-input chemical control of protein dimerization for programming graded cellular responses. Foight GW, Wang Z, Wei CT, Jr Greisen P, Warner KM, Cunningham-Bryant D, Park K, Brunette TJ, Sheffler W, Baker D, Maly DJ. Nat Biotechnol 37 1209-1216 (2019)
  12. Pulmonary fibrosis distal airway epithelia are dynamically and structurally dysfunctional. Stancil IT, Michalski JE, Davis-Hall D, Chu HW, Park JA, Magin CM, Yang IV, Smith BJ, Dobrinskikh E, Schwartz DA. Nat Commun 12 4566 (2021)
  13. Structural basis of the activation of c-MET receptor. Uchikawa E, Chen Z, Xiao GY, Zhang X, Bai XC. Nat Commun 12 4074 (2021)
  14. EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer. Rose M, Maurer A, Wirtz J, Bleilevens A, Waldmann T, Wenz M, Eyll M, Geelvink M, Gereitzig M, Rüchel N, Denecke B, Eltze E, Herrmann E, Toma M, Horst D, Grimm T, Denzinger S, Ecke T, Vögeli TA, Knuechel R, Maurer J, Gaisa NT. Oncogene 39 6856-6870 (2020)
  15. Machine-learning based radiogenomics analysis of MRI features and metagenes in glioblastoma multiforme patients with different survival time. Liao X, Cai B, Tian B, Luo Y, Song W, Li Y. J Cell Mol Med 23 4375-4385 (2019)
  16. WFDC2 suppresses prostate cancer metastasis by modulating EGFR signaling inactivation. Xiong Y, Yuan L, Chen S, Xu H, Peng T, Ju L, Wang G, Xiao Y, Wang X. Cell Death Dis 11 537 (2020)
  17. A molecular mechanism for the generation of ligand-dependent differential outputs by the epidermal growth factor receptor. Huang Y, Ognjenovic J, Karandur D, Miller K, Merk A, Subramaniam S, Kuriyan J. Elife 10 e73218 (2021)
  18. Deep mutational analysis reveals functional trade-offs in the sequences of EGFR autophosphorylation sites. Cantor AJ, Shah NH, Kuriyan J. Proc Natl Acad Sci U S A 115 E7303-E7312 (2018)
  19. Kinetics of receptor tyrosine kinase activation define ERK signaling dynamics. Kiyatkin A, van Alderwerelt van Rosenburgh IK, Klein DE, Lemmon MA. Sci Signal 13 eaaz5267 (2020)
  20. DDR1 autophosphorylation is a result of aggregation into dense clusters. Corcoran DS, Juskaite V, Xu Y, Görlitz F, Alexandrov Y, Dunsby C, French PMW, Leitinger B. Sci Rep 9 17104 (2019)
  21. Structures of the HER2-HER3-NRG1β complex reveal a dynamic dimer interface. Diwanji D, Trenker R, Thaker TM, Wang F, Agard DA, Verba KA, Jura N. Nature 600 339-343 (2021)
  22. Glioblastoma mutations alter EGFR dimer structure to prevent ligand bias. Hu C, Leche CA, Kiyatkin A, Yu Z, Stayrook SE, Ferguson KM, Lemmon MA. Nature 602 518-522 (2022)
  23. Mechanism of Allosteric Coupling into and through the Plasma Membrane by EGFR. Sinclair JKL, Walker AS, Doerner AE, Schepartz A. Cell Chem Biol 25 857-870.e7 (2018)
  24. Dimerization of the Trk receptors in the plasma membrane: effects of their cognate ligands. Ahmed F, Hristova K. Biochem J 475 3669-3685 (2018)
  25. E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function. Godwin TD, Kelly ST, Brew TP, Bougen-Zhukov NM, Single AB, Chen A, Stylianou CE, Harris LD, Currie SK, Telford BJ, Beetham HG, Evans GB, Black MA, Guilford PJ. Gastric Cancer 22 273-286 (2019)
  26. Allosteric activation of T cell antigen receptor signaling by quaternary structure relaxation. Lanz AL, Masi G, Porciello N, Cohnen A, Cipria D, Prakaash D, Bálint Š, Raggiaschi R, Galgano D, Cole DK, Lepore M, Dushek O, Dustin ML, Sansom MSP, Kalli AC, Acuto O. Cell Rep 36 109375 (2021)
  27. Architecture of the Sema3A/PlexinA4/Neuropilin tripartite complex. Lu D, Shang G, He X, Bai XC, Zhang X. Nat Commun 12 3172 (2021)
  28. Dysregulation of FOXD2-AS1 promotes cell proliferation and migration and predicts poor prognosis in oral squamous cell carcinoma: a study based on TCGA data. Liu Z, Zhou W, Lin C, Wang X, Zhang X, Zhang Y, Yang R, Chen W, Cao W. Aging (Albany NY) 13 2379-2396 (2020)
  29. EGFR forms ligand-independent oligomers that are distinct from the active state. Byrne PO, Hristova K, Leahy DJ. J Biol Chem 295 13353-13362 (2020)
  30. Membrane Association Transforms an Inert Anti-TCRβ Fab' Ligand into a Potent T Cell Receptor Agonist. Lin JJ, O'Donoghue GP, Wilhelm KB, Coyle MP, Low-Nam ST, Fay NC, Alfieri KN, Groves JT. Biophys J 118 2879-2893 (2020)
  31. Revisiting a controversy: The effect of EGF on EGFR dimer stability. Singh DR, King C, Salotto M, Hristova K. Biochim Biophys Acta Biomembr 1862 183015 (2020)
  32. Phosphorylation-Dependent Conformations of the Disordered Carboxyl-Terminus Domain in the Epidermal Growth Factor Receptor. Regmi R, Srinivasan S, Latham AP, Kukshal V, Cui W, Zhang B, Bose R, Schlau-Cohen GS. J Phys Chem Lett 11 10037-10044 (2020)
  33. Substratum stiffness regulates Erk signaling dynamics through receptor-level control. Farahani PE, Lemke SB, Dine E, Uribe G, Toettcher JE, Nelson CM. Cell Rep 37 110181 (2021)
  34. Epiregulin promotes trophoblast epithelial-mesenchymal transition through poFUT1 and O-fucosylation by poFUT1 on uPA. Cui X, Wang H, Li Y, Chen T, Liu S, Yan Q. Cell Prolif 53 e12745 (2020)
  35. Four-color single-molecule imaging with engineered tags resolves the molecular architecture of signaling complexes in the plasma membrane. Sotolongo Bellón J, Birkholz O, Richter CP, Eull F, Kenneweg H, Wilmes S, Rothbauer U, You C, Walter MR, Kurre R, Piehler J. Cell Rep Methods 2 100165 (2022)
  36. Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers. Choi B, Cha M, Eun GS, Lee DH, Lee S, Ehsan M, Chae PS, Heo WD, Park Y, Yoon TY. Elife 9 e53934 (2020)
  37. Targeted Delivery of 111In Into the Nuclei of EGFR Overexpressing Cells via Modular Nanotransporters With Anti-EGFR Affibody. Karyagina TS, Ulasov AV, Slastnikova TA, Rosenkranz AA, Lupanova TN, Khramtsov YV, Georgiev GP, Sobolev AS. Front Pharmacol 11 176 (2020)
  38. The Biased Ligands NGF and NT-3 Differentially Stabilize Trk-A Dimers. Ahmed F, Zapata-Mercado E, Rahman S, Hristova K. Biophys J 120 55-63 (2021)
  39. Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation. Lee HH, Wang YN, Yang WH, Xia W, Wei Y, Chan LC, Wang YH, Jiang Z, Xu S, Yao J, Qiu Y, Hsu YH, Hwang WL, Yan M, Cha JH, Hsu JL, Shen J, Ye Y, Wu X, Hou MF, Tseng LM, Wang SC, Pan MR, Yang CH, Wang YL, Yamaguchi H, Pang D, Hortobagyi GN, Yu D, Hung MC. Nat Commun 12 2788 (2021)
  40. The biophysical basis of receptor tyrosine kinase ligand functional selectivity: Trk-B case study. Ahmed F, Paul MD, Hristova K. Biochem J 477 4515-4526 (2020)
  41. An EGFR ligand promotes EGFR-mutant but not KRAS-mutant lung cancer in vivo. Tomoshige K, Guo M, Tsuchiya T, Fukazawa T, Fink-Baldauf IM, Stuart WD, Naomoto Y, Nagayasu T, Maeda Y. Oncogene 37 3894-3908 (2018)
  42. Ginkgolic acid inhibits the growth of renal cell carcinoma cells via inactivation of the EGFR signaling pathway. Zhu C, Na N, Sheng H, Feng B, Wang H, Zhu P, Zhang W, Zhang M, Deng Z. Exp Ther Med 19 2949-2956 (2020)
  43. Multisite EGFR phosphorylation is regulated by adaptor protein abundances and dimer lifetimes. Salazar-Cavazos E, Nitta CF, Mitra ED, Wilson BS, Lidke KA, Hlavacek WS, Lidke DS. Mol Biol Cell 31 695-708 (2020)
  44. Oncogenic KRAS promotes growth of lung cancer cells expressing SLC3A2-NRG1 fusion via ADAM17-mediated shedding of NRG1. Shin DH, Kim SH, Choi M, Bae YK, Han C, Choi BK, Kim SS, Han JY. Oncogene 41 280-292 (2022)
  45. Redundant roles of EGFR ligands in the ERK activation waves during collective cell migration. Lin S, Hirayama D, Maryu G, Matsuda K, Hino N, Deguchi E, Aoki K, Iwamoto R, Terai K, Matsuda M. Life Sci Alliance 5 e202101206 (2022)
  46. Uropathogenic Escherichia coli invades bladder epithelial cells by activating kinase networks in host cells. Kim WJ, Shea AE, Kim JH, Daaka Y. J Biol Chem 293 16518-16527 (2018)
  47. Determinants of Ligand Specificity and Functional Plasticity in Type I Interferon Signaling. Kirby D, Parmar B, Fathi S, Marwah S, Nayak CR, Cherepanov V, MacParland S, Feld JJ, Altan-Bonnet G, Zilman A. Front Immunol 12 748423 (2021)
  48. Differential effects of epidermal growth factor (EGF) receptor ligands on receptor binding, downstream signalling pathways and DNA synthesis in hepatocytes. Ødegård J, Sondresen JE, Aasrum M, Tveteraas IH, Guren TK, Christoffersen T, Thoresen GH. Growth Factors 35 239-248 (2017)
  49. Fyn and TOM1L1 are recruited to clathrin-coated pits and regulate Akt signaling. Cabral-Dias R, Lucarelli S, Zak K, Rahmani S, Judge G, Abousawan J, DiGiovanni LF, Vural D, Anderson KE, Sugiyama MG, Genc G, Hong W, Botelho RJ, Fairn GD, Kim PK, Antonescu CN. J Cell Biol 221 e201808181 (2022)
  50. Increasing kinase domain proximity promotes MST2 autophosphorylation during Hippo signaling. Tran T, Mitra J, Ha T, Kavran JM. J Biol Chem 295 16166-16179 (2020)
  51. Tideglusib promotes wound healing in aged skin by activating PI3K/Akt pathway. Sun J, Zhao H, Shen C, Li S, Zhang W, Ma J, Li Z, Zhang M, Yang J. Stem Cell Res Ther 13 269 (2022)
  52. Comprehensive Model for Epidermal Growth Factor Receptor Ligand Binding Involving Conformational States of the Extracellular and the Kinase Domains. Hajdu T, Váradi T, Rebenku I, Kovács T, Szöllösi J, Nagy P. Front Cell Dev Biol 8 776 (2020)
  53. Deficiency of GABARAP but not its Paralogs Causes Enhanced EGF-induced EGFR Degradation. Dobner J, Simons IM, Rufinatscha K, Hänsch S, Schwarten M, Weiergräber OH, Abdollahzadeh I, Gensch T, Bode JG, Hoffmann S, Willbold D. Cells 9 E1296 (2020)
  54. Functionally selective signaling and broad metabolic benefits by novel insulin receptor partial agonists. Wu M, Carballo-Jane E, Zhou H, Zafian P, Dai G, Liu M, Lao J, Kelly T, Shao D, Gorski J, Pissarnitski D, Kekec A, Chen Y, Previs SF, Scapin G, Llorente YG, Hollingsworth SA, Yan L, Feng D, Huo P, Walford G, Erion MD, Kelley DE, Lin S, Mu J. Nat Commun 13 942 (2022)
  55. Ligand-induced transmembrane conformational coupling in monomeric EGFR. Srinivasan S, Regmi R, Lin X, Dreyer CA, Chen X, Quinn SD, He W, Coleman MA, Carraway KL, Zhang B, Schlau-Cohen GS. Nat Commun 13 3709 (2022)
  56. MET Activation by a Macrocyclic Peptide Agonist that Couples to Biological Responses Differently from HGF in a Context-Dependent Manner. Miao W, Sakai K, Imamura R, Ito K, Suga H, Sakuma T, Yamamoto T, Matsumoto K. Int J Mol Sci 19 E3141 (2018)
  57. Monitoring activities of receptor tyrosine kinases using a universal adapter in genetically encoded split TEV assays. Wintgens JP, Wichert SP, Popovic L, Rossner MJ, Wehr MC. Cell Mol Life Sci 76 1185-1199 (2019)
  58. Nanopore-mediated protein delivery enabling three-color single-molecule tracking in living cells. Chen Z, Cao Y, Cao Y, Lin CW, Alvarez S, Oh D, Yang P, Groves JT. Proc Natl Acad Sci U S A 118 e2012229118 (2021)
  59. Targeting epiregulin in the treatment-damaged tumor microenvironment restrains therapeutic resistance. Wang C, Long Q, Fu Q, Xu Q, Fu D, Li Y, Gao L, Guo J, Zhang X, Lam EW, Campisi J, Sun Y. Oncogene 41 4941-4959 (2022)
  60. The Combination of Gefitinib With ATRA and ATO Induces Myeloid Differentiation in Acute Promyelocytic Leukemia Resistant Cells. de Almeida LY, Pereira-Martins DA, Weinhäuser I, Ortiz C, Cândido LA, Lange AP, De Abreu NF, Mendonza SES, de Deus Wagatsuma VM, Do Nascimento MC, Paiva HH, Alves-Paiva RM, Bonaldo CCOM, Nascimento DC, Alves-Filho JC, Scheucher PS, Lima ASG, Schuringa JJ, Ammantuna E, Ottone T, Noguera NI, Araujo CL, Rego EM. Front Oncol 11 686445 (2021)
  61. Pparγ1 Facilitates ErbB2-Mammary Adenocarcinoma in Mice. Jiao X, Tian L, Zhang Z, Balcerek J, Kossenkov AV, Casimiro MC, Wang C, Liu Y, Ertel A, Soccio RE, Chen ER, Liu Q, Ashton AW, Tong W, Pestell RG. Cancers (Basel) 13 2171 (2021)
  62. EGFR Activation Impairs Antiviral Activity of Interferon Signaling in Brain Microvascular Endothelial Cells During Japanese Encephalitis Virus Infection. Zhang YG, Chen HW, Zhang HX, Wang K, Su J, Chen YR, Wang XR, Fu ZF, Cui M. Front Microbiol 13 894356 (2022)
  63. EGFR signal transduction is downregulated in C. elegans vulval precursor cells during dauer diapause. O'Keeffe C, Greenwald I. Development 149 dev201094 (2022)
  64. EGFR-Targeted Cellular Delivery of Therapeutic Nucleic Acids Mediated by Boron Clusters. Kaniowski D, Suwara J, Ebenryter-Olbińska K, Jakóbik-Kolon A, Nawrot B. Int J Mol Sci 23 14793 (2022)
  65. Fluorescently tagged nanobodies and NanoBRET to study ligand-binding and agonist-induced conformational changes of full-length EGFR expressed in living cells. Comez D, Glenn J, Anbuhl SM, Heukers R, Smit MJ, Hill SJ, Kilpatrick LE. Front Immunol 13 1006718 (2022)
  66. High-Precision Protein-Tracking With Interferometric Scattering Microscopy. Taylor RW, Holler C, Mahmoodabadi RG, Küppers M, Dastjerdi HM, Zaburdaev V, Schambony A, Sandoghdar V. Front Cell Dev Biol 8 590158 (2020)
  67. Identification of Cellular Factors Required for SARS-CoV-2 Replication. Synowiec A, Jedrysik M, Branicki W, Klajmon A, Lei J, Owczarek K, Suo C, Szczepanski A, Wang J, Zhang P, Labaj PP, Pyrc K. Cells 10 3159 (2021)
  68. Leader cell PLCγ1 activation during keratinocyte collective migration is induced by EGFR localization and clustering. Kim CS, Yang X, Jacobsen S, Masters KS, Kreeger PK. Bioeng Transl Med 4 e10138 (2019)
  69. Regulation of the alveolar regenerative niche by amphiregulin-producing regulatory T cells. Kaiser KA, Loffredo LF, Santos-Alexis KL, Ringham OR, Arpaia N. J Exp Med 220 e20221462 (2023)
  70. The Cytotoxicity of RNase-Derived Peptides. Ulyanova V, Dudkina E, Nadyrova A, Kalashnikov V, Surchenko Y, Ilinskaya O. Biomolecules 11 E16 (2020)
  71. The dependence of EGFR oligomerization on environment and structure: A camera-based N&B study. Balasubramanian H, Sankaran J, Pandey S, Goh CJH, Wohland T. Biophys J 121 4452-4466 (2022)
  72. Unveiling functional motions based on point mutations in biased signaling systems: A normal mode study on nerve growth factor bound to TrkA. Resende-Lara PT, Perahia D, Scott AL, Braz ASK. PLoS One 15 e0231542 (2020)
  73. Binding of single-mutant epidermal growth factor (EGF) ligands alters the stability of the EGF receptor dimer and promotes growth signaling. Pascarelli S, Merzhakupova D, Uechi GI, Laurino P. J Biol Chem 297 100872 (2021)
  74. Comparison of tyrosine kinase domain properties for the neurotrophin receptors TrkA and TrkB. Artim SC, Kiyatkin A, Lemmon MA. Biochem J 477 4053-4070 (2020)
  75. EGFR transactivates RON to drive oncogenic crosstalk. Franco Nitta C, Green EW, Jhamba ED, Keth JM, Ortiz-Caraveo I, Grattan RM, Schodt DJ, Gibson AC, Rajput A, Lidke KA, Wilson BS, Steinkamp MP, Lidke DS. Elife 10 e63678 (2021)
  76. Enzyme Prodrug Therapy with Photo-Cross-Linkable Anti-EGFR Affibodies Conjugated to Upconverting Nanoparticles. Roy S, Curry SD, Corbella Bagot C, Mueller EN, Mansouri AM, Park W, Cha JN, Goodwin AP. ACS Nano 16 15873-15883 (2022)
  77. Epiregulin is a dendritic cell-derived EGFR ligand that maintains skin and lung fibrosis. Odell ID, Steach H, Gauld SB, Reinke-Breen L, Karman J, Carr TL, Wetter JB, Phillips L, Hinchcliff M, Flavell RA. Sci Immunol 7 eabq6691 (2022)
  78. Epiregulin, epigen and betacellulin antibodies and axial elongation in young guinea pigs with lens-induced myopization. Dong L, Zhang RH, Zhou WD, Li YF, Li HY, Wu HT, Shi XH, Jonas JB, Wei WB. BMC Ophthalmol 22 193 (2022)
  79. Functional genomic characterization of a synthetic anti-HER3 antibody reveals a role for ubiquitination by RNF41 in the anti-proliferative response. Turowec JP, Lau EWT, Wang X, Brown KR, Fellouse FA, Jawanda KK, Pan J, Moffat J, Sidhu SS. J Biol Chem 294 1396-1409 (2019)
  80. Liver X receptor agonists exert antitumor effects against hepatocellular carcinoma via inducing REPS2 expression. He XY, Zhu MM, Zheng J, Wang CY, Zhao XK, Zhang BT, Zhou DC, Zhang S, Yang XX, Duan YJ, Han JH, Chen YL. Acta Pharmacol Sin 44 635-646 (2023)
  81. Membrane signalosome: where biophysics meets systems biology. Kandy SK, Janmey PA, Radhakrishnan R. Curr Opin Syst Biol 25 34-41 (2021)
  82. Nucleus Near-Infrared (nNIR) Irradiation of Single A549 Cells Induces DNA Damage and Activates EGFR Leading to Mitochondrial Fission. Gbetuwa M, Lu LS, Wang TJ, Chen YJ, Chiou JF, Su TY, Yang TS. Cells 11 624 (2022)
  83. PDGFR dimer-specific activation, trafficking and downstream signaling dynamics. Rogers MA, Campaña MB, Long R, Fantauzzo KA. J Cell Sci 135 jcs259686 (2022)
  84. Stoichiometry counts. Chao MV. Proc Natl Acad Sci U S A 116 21343-21345 (2019)
  85. Structural insights into EphA4 unconventional activation from prediction of the EphA4 and its complex with ribonuclease 1. Li YC, Yamaguchi H, Liu YY, Hsu KC, Sun TH, Sun PC, Hung MC. Am J Cancer Res 12 4865-4878 (2022)
  86. Structure and dynamics of the EGFR/HER2 heterodimer. Bai X, Sun P, Wang X, Long C, Liao S, Dang S, Zhuang S, Du Y, Zhang X, Li N, He K, Zhang Z. Cell Discov 9 18 (2023)
  87. A cross-reactive pH-dependent EGFR antibody with improved tumor selectivity and penetration obtained by structure-guided engineering. Liu X, Tian X, Hao X, Zhang H, Wang K, Wei Z, Wei X, Li Y, Sui J. Mol Ther Oncolytics 27 256-269 (2022)
  88. A guide to ERK dynamics, part 1: mechanisms and models. Ram A, Murphy D, DeCuzzi N, Patankar M, Hu J, Pargett M, Albeck JG. Biochem J 480 1887-1907 (2023)
  89. A single amino acid substitution in CXCL12 confers functional selectivity at the beta-arrestin level. Rigo A, Ferrarini I, Innamorati G, Vinante F. Oncotarget 9 28830-28841 (2018)
  90. An effective strategy for ligand-mediated pulldown of the HER2/HER3/NRG1β heterocomplex and cryo-EM structure determination at low sample concentrations. Trenker R, Diwanji D, Verba KA, Jura N. Methods Enzymol 667 633-662 (2022)
  91. Biased activation of the receptor tyrosine kinase HER2. Catapano C, Rahm JV, Omer M, Teodori L, Kjems J, Dietz MS, Heilemann M. Cell Mol Life Sci 80 158 (2023)
  92. Binding sites in the epidermal growth factor receptor are responsible for bisphenol S effects on trophoblast cell invasion. Ticiani E, Villegas JA, Murga-Zamalloa C, Veiga-Lopez A. Chemosphere 318 137960 (2023)
  93. Blocking EREG/GPX4 Sensitizes Head and Neck Cancer to Cetuximab through Ferroptosis Induction. Jehl A, Conrad O, Burgy M, Foppolo S, Vauchelles R, Ronzani C, Etienne-Selloum N, Chenard MP, Danic A, Dourlhes T, Thibault C, Schultz P, Dontenwill M, Martin S. Cells 12 733 (2023)
  94. Budding uninhibited by benzimidazoles-1 (BUB1) regulates EGFR signaling by reducing EGFR internalization. Nyati S, Young G, Speers C, Nyati MK, Rehemtulla A. Aging (Albany NY) 15 6011-6030 (2023)
  95. Cellular Uptake of Silica Particles Influences EGFR Signaling Pathway and is Affected in Response to EGF. Sousa de Almeida M, Roshanfekr A, Balog S, Petri-Fink A, Rothen-Rutishauser B. Int J Nanomedicine 18 1047-1061 (2023)
  96. Cellular context alters EGF-induced ERK dynamics and reveals potential crosstalk with GDF-15. Krause HB, Karls AL, McClean MN, Kreeger PK. Biomicrofluidics 16 054104 (2022)
  97. Epiregulin as an Alternative Ligand for Leptin Receptor Alleviates Glucose Intolerance without Change in Obesity. Song NJ, Lee A, Yasmeen R, Shen Q, Yang K, Kumar SB, Muhanna D, Arnipalli S, Noria SF, Needleman BJ, Hazey JW, Mikami DJ, Ortega-Anaya J, Jiménez-Flores R, Prokop J, Ziouzenkova O. Cells 11 425 (2022)
  98. ErbBs in Lens Cell Fibrosis and Secondary Cataract. VanSlyke JK, Boswell BA, Musil LS. Invest Ophthalmol Vis Sci 64 6 (2023)
  99. Fibroblast-derived EGF ligand neuregulin 1 induces fetal-like reprogramming of the intestinal epithelium without supporting tumorigenic growth. Lemmetyinen TT, Viitala EW, Wartiovaara L, Kaprio T, Hagström J, Haglund C, Katajisto P, Wang TC, Domènech-Moreno E, Ollila S. Dis Model Mech 16 dmm049692 (2023)
  100. Inferring ligand-receptor cellular networks from bulk and spatial transcriptomic datasets with BulkSignalR. Villemin JP, Bassaganyas L, Pourquier D, Boissière F, Cabello-Aguilar S, Crapez E, Tanos R, Cornillot E, Turtoi A, Colinge J. Nucleic Acids Res gkad352 (2023)
  101. NanoB2 to monitor interactions of ligands with membrane proteins by combining nanobodies and NanoBRET. van den Bor J, Bergkamp ND, Anbuhl SM, Dekker F, Comez D, Perez Almeria CV, Bosma R, White CW, Kilpatrick LE, Hill SJ, Siderius M, Smit MJ, Heukers R. Cell Rep Methods 3 100422 (2023)
  102. Piezo1 activates noncanonical EGFR endocytosis and signaling. Pardo-Pastor C, Rosenblatt J. Sci Adv 9 eadi1328 (2023)
  103. Proximity extracellular protein-protein interaction analysis of EGFR using AirID-conjugated fragment of antigen binding. Yamada K, Shioya R, Nishino K, Furihata H, Hijikata A, Kaneko MK, Kato Y, Shirai T, Kosako H, Sawasaki T. Nat Commun 14 8301 (2023)
  104. Quantification of ligand and mutation-induced bias in EGFR phosphorylation in direct response to ligand binding. Wirth D, Özdemir E, Hristova K. Nat Commun 14 7579 (2023)
  105. Quantitative assessment of ligand bias from bias plots: The bias coefficient "kappa". Karl K, Rajagopal S, Hristova K. Biochim Biophys Acta Gen Subj 1867 130428 (2023)
  106. Sialylation of EGFR by ST6GAL1 induces receptor activation and modulates trafficking dynamics. Ankenbauer KE, Rao TC, Mattheyses AL, Bellis SL. J Biol Chem 299 105217 (2023)
  107. Systematic pharmacological analysis of agonistic and antagonistic fibroblast growth factor receptor 1 MAbs reveals a similar unique mode of action. Chan J, Chan J, Shao L, Stawicki SS, Pham VC, Akita RW, Hafner M, Crocker L, Yu K, Koerber JT, Schaefer G, Comps-Agrar L. J Biol Chem 299 102729 (2023)
  108. TRPV1 inhibition overcomes cisplatin resistance by blocking autophagy-mediated hyperactivation of EGFR signaling pathway. Oh SJ, Lim JY, Son MK, Ahn JH, Song KH, Lee HJ, Kim S, Cho EH, Chung JY, Cho H, Kim H, Kim JH, Park J, Choi J, Hwang SW, Kim TW. Nat Commun 14 2691 (2023)
  109. The association of urinary epidermal growth factors with ADPKD disease severity and progression. Harskamp LR, Perez-Gomez MV, Heida JE, Engels GE, van Goor H, van den Heuvel MC, Streets AJ, Ong ACM, Ortiz A, Gansevoort RT, DIPAK Consortium. Nephrol Dial Transplant 38 2266-2275 (2023)
  110. The effector program of human CD8 T cells supports tissue remodeling. Delacher M, Schmidleithner L, Simon M, Stüve P, Sanderink L, Hotz-Wagenblatt A, Wuttke M, Schambeck K, Ruhland B, Hofmann V, Bittner S, Ritter U, Pant A, Helbich SS, Voss M, Lemmermann NA, Bessiri-Schake L, Bohn T, Eigenberger A, Menevse AN, Gebhard C, Strieder N, Abken H, Rehli M, Huehn J, Beckhove P, Hehlgans T, Junger H, Geissler EK, Prantl L, Werner JM, Schmidl C, Brors B, Imbusch CD, Feuerer M. J Exp Med 221 e20230488 (2024)
  111. pYtags enable spatiotemporal measurements of receptor tyrosine kinase signaling in living cells. Farahani PE, Yang X, Mesev EV, Fomby KA, Brumbaugh-Reed EH, Bashor CJ, Nelson CM, Toettcher JE. Elife 12 e82863 (2023)


Quick links